Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Becton, Dickinson Banks On Bard Buyout, Medical Unit Weak

By Zacks Investment ResearchStock MarketsDec 13, 2017 08:11PM ET
www.investing.com/analysis/becton-dickinson-banks-on-bard-buyout-medical-unit-weak-200273262
Becton, Dickinson Banks On Bard Buyout, Medical Unit Weak
By Zacks Investment Research   |  Dec 13, 2017 08:11PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
MDT
+0.11%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BDX
-1.07%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BCR
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MMSI
-1.55%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

On Dec 13, 2017, we issued an updated research report on, Becton, Dickinson and Company (NYSE:BDX) , popularly known as BD. The stock carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The leading MedTech company is steadily progressing with the acquisition of C. R. Bard (NYSE:BCR) . Post completion, BD expects growth in adjusted earnings starting fiscal 2019. The acquisition will enable the company generate profits from complementary businesses and geographical expansion.

On Nov 16, BD announced that it will divest soft tissue core needle biopsy products for $100M to Merit Medical Systems Inc. (NASDAQ:MMSI) . The products are currently sold under Bard's Aspira product line of tunneled home drainage catheters and accessories. The divestment is contingent on the completion of the BD’s acquisition of Bard.

Year to date, BD has outperformed the industry in terms of stock price. The company has returned 34.2%, comparing favorably with the industry’s rally of just 21.3%. Notably, the current return is relatively higher than the S&P 500’s increase of 21.9%.

On the flip side, lackluster performance by BD’s Medical Unit is a concern. Performance in the segment is affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States.

Within the Diabetes Care unit, BD temporarily has paused shipments of insulin infusion sets, thanks to higher-than-anticipated rate of complaints associated with insertion during the pilot launch of the product. However, management conducted a clinical trial to gather insights and ensure that patients ultimately realize the full benefits of BD FlowSmart technology. BD continues to collaborate with Medtronic Plc (NYSE:MDT) toward full commercialization of the product

Adding to woes, the ongoing political conundrum pertaining to the repealing of Obamacare by the Republicans has given rise to uncertainties for dental stocks like BD and CONMED Corporation. Thus, lack of favorable developments in the regulatory front is a concern for these MedTech majors.

Zacks Editor-in-Chief Goes ""All In"" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>



Medtronic PLC (MDT): Free Stock Analysis Report

C.R. Bard, Inc. (BCR): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

Original post

Zacks Investment Research

Becton, Dickinson Banks On Bard Buyout, Medical Unit Weak
 

Related Articles

Becton, Dickinson Banks On Bard Buyout, Medical Unit Weak

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email